focus -WSS

focus

author：fashion 2025-09-28 01:38:12 - browse：68583

Aduhelm package — Jessica Rinaldi/The Boston Globe

Biogen is giving up its ownership of Aduhelm, the Alzheimer’s disease treatment whose 2021 approval led to scrutiny and outrage, turning the page on a tempestuous chapter in the company’s long history.

Neurimmune, the Swiss company that invented Aduhelm, will regain full rights to the intravenous medicine, Biogen said Wednesday. Biogen will also terminate an ongoing clinical trial meant to prove the treatment’s benefits for patients in the early stages of Alzheimer’s.

“When searching for new medicines, one breakthrough can be the foundation that triggers future medicines to be developed,” Biogen CEO Christopher Viehbacher said in a statement. “Aduhelm was that groundbreaking discovery that paved the way for a new class of drugs and reinvigorated investments in the field.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： Reanimated hearts work just as well for transplants, study finds

hotspot

explore

WSS

Altering the blood type of lungs raises potential for universal organs for transplants

TB outbreak tied to bone grafts underscores testing shortcomings

An innovative path out of biotech’s “valley of death”

Pharma budget tightening trickles down to Doximity

Novo: Oral version of Ozempic leads to 15% weight loss

Kim Kardashian sparks debate on benefits of full

entertainment

focus

knowledge

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Where are patients getting their prescriptions for GLP

Peter Hotez and the public health issue of online harassment

Eli Lilly’s Mounjaro succeeds in second weight

Walensky prepares to leave CDC — and Congress — behind

Biden administration plans revamp of organ transplant system

Dobbs anniversary: the lost opportunity of abortion as health care

Pharma budget tightening trickles down to Doximity

Medicare details structure of new drug price negotiation program

Timeline: Key moments in fight for gay rights

focus

Correcting Robert F. Kennedy Jr.'s vaccine 'facts'

Large hospital system sues Multiplan for low

Eli Lilly’s Mounjaro succeeds in second weight

After John Oliver segment, STAT readers share their opioid

Eli Lilly’s Mounjaro succeeds in second weight

We're not in Australia anymore: Kansas cops jump into action to save kangaroo

knowledge

hotspot

explore

hotspot